Cannabis sativa Extract
Phase 1Small molecule
Cannabis sativa Extract is one of 34 small molecule programs targeting Cannabis Dependence. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Cannabis Dependence
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisApproved
Nicorette
PfizerApproved
Buspar
Bristol-Myers SquibbApproved
Viibryd
AbbVieApproved
Lioresal
NovartisApproved
Revia
TevaApproved
Rozerem
TakedaApproved
Epidiolex
Jazz PharmaceuticalsApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Prometrium
FerringApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cannabis sativa Extract. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRoswell Park Cancer Institute